The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy

• Status: Unknown status
• Trial end date: 2013-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators' Hypothesis is that "The correct timing of gametocytocidal drug in combination with an effective Artemisinin Combination Therapy can limit the infectiousness of malaria-infected individuals to less than one week after initiation of treatment"

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kilimanjaro Clinical Research Institute
• Collaborators: Ifakara Health Institute; London School of Hygiene and Tropical Medicine
• Treatments: Artemether; Artemether-lumefantrine combination; Artemether, Lumefantrine Drug Combination; Artemisinine; Artemisinins; Lumefantrine; Primaquine

Criteria

Inclusion Criteria:

• Age 3 years - 17 years

• Residents of research area

• Willingness to come for complete scheduled follow-up.

• Uncomplicated malaria with P. falciparum mono-infection

• Axillary temperature > 37.5°C and < 39.5°C, or history of fever in previous 48 hours.

• No history of adverse reactions to study medication

• Understanding of the procedures of the study by parent or guardian and willing to participate by signing written informed consent forms

Exclusion Criteria:

• Haemoglobin below 9g/dl

• Inability to take drugs orally

• Known hypersensitivity to any of the drugs given

• Reported treatment with antimalarial chemotherapy in the past 2 weeks

• Evidence of chronic disease or acute infection other than malaria

• Domicile outside the study area

• Signs of severe malaria( such as respiratory distress, altered consciousness deep breathing, anaemia)

• Participating in other malaria studies conducted in the region

• Mixed malaria parasite species infection

• Positive pregnant test by Urine (UPT) if participant is female aged above 12 years

• G6PD deficient using the fluorescence spot test